We used an experimental model of sympathetic neuropathy to investigate the effects of intraperitoneal cholecystokinin-8 (CCK-8) administration on the recovery of injured peripheral neurones. After treatment of adult mice with 6-hydroxydopamine (6-OHDA), which is known to induce peripheral sympathectomy, nerve growth factor (NGF) in peripheral tissue ®rst increased and then rapidly decreased to baseline levels. Following this observation, sympathectomised mice were treated with CCK-8 starting when the NGF levels lowered toward the control value. Our results show that injections with 8 nmol/kg of CCK-8 promote not only recovery of noradrenergic innervation but also NGF and neuropeptide Y (NPY) synthesis in peripheral tissue. This latter observation suggests that the effect of CCK-8 might be mediated through the stimulation of NGF synthesis.
INTRODUCTION
Peripheral sympathectomy of laboratory animals is a useful experimental model for examining the action of biologically active compounds on neuronal plasticity and the functional relationship between nerve cells and innervated organs [1, 2] . Speci®cally, the use of chemical sympathectomy has helped to characterise the role of neurotrophic factors in structural, biochemical and functional recovery of peripheral injured neurites and has stimulated clinical interest in these molecules [1, 3] , pointing to a possible utilisation of neurotrophins and in particular of the nerve growth factor (NGF) in human neurodegenerative disorders. Numerous studies, both in animal models and in humans, have demonstrated that sympathetic neurones are highly dependent on NGF not only during development, but also in adult life [2] . NGF acts as a neurone survival factor and is involved in phenotypic differentiation of sympathetic neurones [4] . Despite this evidence, it is still debated whether NGF can be used therapeutically for human peripheral neuropathies. Indeed one important limitation is the possibility of exogenous NGF producing undesired side effects, such as peripheral hyperalgesia [5, 6] . One potential approach to overcome this undesired effect of NGF is to identify molecules that have the ability to promote synthesis and release of endogenous NGF from NGF-producing cells.
We previously reported that injection with cholecystokinin-8 (CCK-8), a neuropeptide widely distributed in the central (CNS) and peripheral nervous system (PNS), promotes structural and biochemical recovery of lesioned forebrain cholinergic neurones and that the enhanced synthesis and release of NGF mediate this effect [7, 8] . CCK-8 expression increases following nerve injury [9, 10] and/or NGF deprivation [11] , suggesting a role for CCK-8 in the mechanism of peripheral nerve repair. To gain further information regarding the involvement of this neuropeptide on the peripheral nervous system, we injected CCK-8 into adult sympathectomised rodents. To induce peripheral sympathectomy we used the neurotoxic compound 6-hydroxydopamine (6-0HDA) [12] . The present study was designed to investigate whether CCK-8 administration promoted peripheral catecholaminergic sympathetic nerve regeneration and NGF synthesis in target tissues innervated by sympathetic nerve ®bres.
MATERIALS AND METHODS
Animals: Three-month-old male mice of the CD-1 strain, purchased from Charles River (Calco, Italy), were housed 4±5/cage under a 12:12 h light:dark cycle with water and food ad lib. Animal care and procedures were conducted in conformity with the intramural committee and institutional guidelines in accordance with national and international laws (EEC directive 86/609, OJ L 358, 1, December 12, 1987 ).
Treatment with 6-OHDA and CCK-8: 6-OHDA (Fluka AG, Germany) was dissolved in distilled water containing 0.9% sodium chloride (saline solution) and 0.5 mg/ml ascorbic acid (vehicle solution). To evaluate the time-course expression of NGF in chemically sympathectomised peripheral tissue, a group of 24 mice were treated for 2 consecutive days with 100 mg/kg 6-OHDA. On days 2, 5, 10 and 20 after the injection of the neurotoxin, mice (n 6 for each time point) were sacri®ced, the eyes removed and the amount of NGF evaluated using an enzyme-linked immunosorbent assay (ELISA). Another group of six untreated mice was used as control.
To investigate the effects of CCK-8 on sympathetic neuropathy, we used 48 mice; 24 were treated for two consecutive days with 100 mg/kg 6-OHDA and 24 mice were treated with vehicle solution only. Five days later the animals were divided into four experimental groups and treated as follows: 6-OHDA-treated, injected with CCK-8 (6-OHDA CCK-8; n 12); 6-OHDA-treated, injected with saline solution (6-OHDA saline; n 12); vehicle-treated, injected with CCK-8 (vehicle CCK-8; n 12); vehicletreated, injected with saline solution (vehicle saline group; n 12). CCK-8 (Peninsula Lab., USA; 8 nmol/kg dissolved in saline solution) was injected i.p. once a day for 7 consecutive days, starting 5 days after the last 6-OHDA treatment. The mice were then sacri®ced with an overdose of sodium pentobarbital and the peripheral tissue was removed and immediately frozen until used for NGF or neuropeptide determination.
Evaluation of sympathetic innervation: Mice were sacri®ced, the iris removed and noradrenergic neurites stained using the glyoxylic acid-induced¯uorescence (GAIF) methodology [13] . The preparations were examined under a¯uorescent microscope equipped with excitation and barrier emission ®lters with a transmission cut-off of 470 and 500 mm, respectively. Neurite number in three different areas (total surface 700 ìm 2 ; n 8 iris per group) was estimated by two investigators in a blind fashion and differences among experimental groups were statistically evaluated.
NGF assay: Mice were sacri®ced and peripheral tissues removed and quickly frozen at À708C until neuropeptide and NGF assays were performed. The levels of NGF were measured using monoclonal mouse anti-NGF antibody (clone 27/21, Boehringer Mannheim, Germany) coated on polystyrene 96-well immunoplates (Nunc) for capturing the samples and standard NGF and anti-â-NGF-galactosidase (clone 27/21, Boehringer Mannheim, Germany) for the colorimetric detection [14] . The recovery of NGF during the assay procedure was estimated by adding a known amount of highly puri®ed NGF to the samples or to the homogenization buffer, as internal control. The yield of the exogenous NGF was calculated by subtracting the amount of endogenous NGF from the value of endogenous plus exogenous values. Under these conditions, the NGF recovery was . 90%.
BDNF assay: The concentrations of BDNF were measured with the BDNF Emax immunoassay system number G6891, following the procedure suggested by the manufacturer (Promega, Madison, WI, USA).
RT-PCR: Total RNA was extracted using the Trizol kit (GIBCO, Life Technologies, Rome, Italy) according to the manufacturer's instructions. One microgram of RNA was reverse transcribed into a single stranded cDNA with the reverse transcription system (Promega Italia, Milano, Italy) in a total reaction volume of 20 ìl, using 250 ng oligo(dT) 12±18 primer, 200 units of MLV-RT (Promega Italia, Milano, Italy) and 0.5 U RNasin ribonuclease inhibitor (Promega Italia, Milan, Italy). To compensate for the relative differences in sample size, integrity of the individual RNA samples and the variation in reverse transcription, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was co-ampli®ed with murine NGF. The PCR reaction was carried out in 50 ìl mixtures containing 5 ìl sample cDNA, 5 ìl 103 Taq polymerase buffer (Promega Italia, Milan, Italy), 2.5 mM MgCl 2 , 0.2 mM of each dNTP (Pharmacia Biotech, C. Monzese, Italy) and 12.5 pmol primers (NGF: 59-CAGGACTCACAGGAGCAAGC-39; 59-GCCTTCCTGCTGAGCACACA-39, corresponding respectively to positions 660±679 and 984±1003 of mouse NGF mRNA [15] ; GAPDH: 59-CACCACCATGGAGAAGGCC-39; 59-GATGGATGCCTTGGCCAGG-39 corresponding respectively to positions 346±365 and 517±536 of mouse GAPDH mRNA [16] ) and 2 U Taq polymerase (Promega Italia, Milan, Italy) on a GeneAmp PCR System 9600 thermal cycler (Perkin Elmer Cetus, CA, USA) for 30 cycles (60 s at 958C, 60 s at 558C and 120 s at 728C). The PCR products are a 343 base long fragment of NGF and a 190 base long fragment of GAPDH. After PCR, 20 ìl of undiluted reaction products were loaded onto a 2% agarose MP (Boehringer Mannheim, Monza, Italy) gel containing 1 ìg/ml ethidium bromide. The gel was run at 1 V/cm for 15 min and then at 5 V/cm for 3 h. The DNA-containing bands were photographed using a u.v. transilluminator. The identity of all the PCR products was con®rmed by comparison with the correct size based on the known length of the DNA sequence on an agarose gel and by Southern blotting (data not shown). Band densitometric evaluation, expressed as arbitrary units of grey level, was performed on a Macintosh computer using the public domain NIH Image program (developed at the US National Institutes of Health and available on the Internet at http://rsb.info.nih.gov/ nih-image/), which determines the optical density of the ethidium bromide stained bands using a grey scale thresholding operation. The optical density of GAPDH bands was used as normalising factor.
Neuropeptide Y (NPY) analysis: Tissues were rapidly thawed and boiled in 2 M acetic acid (1 ml/g wet weight) for 15 min, cooled on ice for 10 min, sonicated, centrifuged at 10 000 3 g for 15 min and the supernatants collected for NPY measurement by radioimmunoassay (RIA). The tissue concentration of NPY-like immunoreactivity (NPY-LI) was analysed using antiserum N1 [17] , which cross-reacts 0.1% with avian pancreatic polypeptide but not with other peptides. The detection limit of the assay was 11 pmol/l.
Statistical analysis:
The time-course data were obtained by ANOVA) using the SuperANOVA package for Macintosh (Abacus Concepts Inc., Berkeley, CA, USA). All other data were obtained by a two-way ANOVA, considering sympathectomy and CCK-8 treatment as variables (see Table 1 ). Post-hoc comparisons within logical sets of means were performed using the Tukey's test, the use of which is permissible or even recommended also in the absence of signi®cant main or interaction effects in the ANOVA, in order to minimise frequency errors of both type I and II, following the indications given [18] .
RESULTS
Chemical sympathectomy and endogenous NGF levels: The time-course study ( Fig. 1) shows that 2 days after 6-OHDA treatment the NGF levels in eye increase (1673 AE 349 pg/g vs 258 AE 65 pg/g of controls), and return to baseline levels 1 week later. In the heart, as shown in Fig. 3, 20 days after sympathectomy the amount of NGF is lower than control.
Effects of treatment with CCK-8: To investigate the effects of CCK-8 after sympathectomy, 6-OHDA-treated and untreated mice were injected with CCK-8, starting 5 days after sympathectomy. As shown in Fig. 2, 12 days after chemical sympathectomy the iris of untreated adult mouse (Fig. 2a) displays a dense network of peripheral sympathetic, catecholamine-histo¯uorescent ®bres, while the iris of 6-OHDA-treated adult mouse is almost completely devoid of these ®bres (Fig. 2b) . This result is consistent with previous observations that 6-OHDA in adult mice causes loss of sympathetic nerve ®bres [12] . The treatment with CCK-8 induces an increase of the noradrenergic innervation in the iris of sympathectomised mice (Fig. 2c,  6 -OHDA CCK-8 group) compared with the iris of sympathectomised mice treated with saline (Fig. 2b, 6 -OH-DA saline group). The quantitative evaluation of the number of noradrenergic neurites in the iris of each experimental group is shown in Fig. 2d . No signi®cant differences were noted between vehicle saline group and vehicle CCK-8-treated mice.
Because sympathetic innervation in adult animals is associated with NGF produced by peripheral innervated tissue [4] , the effect of CCK-8 treatment on NGF synthesis in peripheral tissues was also studied. ANOVA (see Table  1 ) indicated that both sympathectomy (F(1,44) 22.1, p , 0.0001) and CCK-8 treatment (F(1,44) 60.5, p , 0.0001) affected NGF levels in the eye. Post-hoc comparison (illustrated in Fig. 3 ) revealed that these effects were mainly due to the high NGF levels in both the CCK-8-treated groups. CCK-8 treatment increased NGF protein levels in eye of normal mice (614 AE 58 pg/g in vehicle CCK-8 vs 327 AE 32 in vehicle saline, p , 0.05). An higher increase of NGF protein was observed in eye of sympathectomised mice injected with CCK-8 (1188 AE 64 pg/g in 6-OH-DA CCK-8 vs 327 AE 32 in vehicle saline, p , 0.05).
Neither sympathectomy (F1,44 0.30, p 0.86) nor the treatment with CCK-8 (F1,44 0.41, p 0.52) seemed to induce signi®cant alteration of the basal NGF levels in the heart, as suggested by ANOVA (Table 1) . However, posthoc comparison (see Fig. 3 ) revealed that NGF levels in the heart of 6-OHDAsaline mice (166 AE 28 pg/g) were lower ( p , 0.05) than the levels measured in both vehiclesaline mice (224 AE 21 pg/g) and in 6-OHDACCK-8 mice (234 AE 19 pg/g). CCK-8 administration induces a signi®cant increase of BDNF in the heart of 6-OHDA-treated mice (saline: 470 AE 45 pg/g; 6-OHDA: 466 AE 42 pg/g; CCK-8: 524 AE 40 pg/g; 6-OHDA CCK-8: 1951 AE 427 pg/g), suggesting that this neuropeptide in¯uences the synthesis not only of NGF but also of BDNF. ANOVA (Table 1 ) and internal post hoc comparisons also showed that sympathectomy affected spleen NGF levels (F(1,44) 14.9, p 0.0004) while CCK-8 treatments did not exert signi®cant effects (F(1,44) 4.0, p 0.051; see Fig. 3 ).
To verify whether CCK-8 affects NGF synthesis, we analysed NGFmRNA expression by RT-PCR. ANOVA results are summarised in Table 1 Fig. 3 . CCK-8 affects NGF expression in peripheral tissues of normal and sympathectomised mice. Exogenous administration of CCK-8 causes an increase of NGF levels in the eye of both normal and sympathectomised mice. Injection with CCK-8 is also able to restore normal NGF values in the heart of sympathectomised mice, while it does not exert any signi®cant effect in the spleen. Data are presented as mean AE s.e.m., n 12 for each group. Statistically signi®cant differences among groups are expressed as follows: a p , 0.05 vs vehicle saline group; b p , 0.05 vs vehicle CCK-8 group; c p , 0.05 vs 6-OHDA saline group.
the heart and spleen of vehicle-treated mice and in the heart of sympathectomised mice. Because NGF is known to in¯uence synthesis of NPY [19] we measured the level of NPY in peripheral tissues. ANOVA (Table 1) showed that sympathectomy decreased NPY in the eye (F(1,44) 19.9, p , 0.0001), in the heart (F(1,44) 13.2, p 0.0007), and in the spleen (F(1,44) 26.8, p , 0.0001). These results are consistent with previous studies showing that NPY is present in peripheral tissues innervated by the sympathetic nervous system and that its levels decrease after axotomy [19] . Administration of CCK-8 up-regulated NPY in the eye (F(1,44) 28.4, p , 0.0001 ) and in the heart (F(1,44) 12.2, p 0.001) but not in the spleen (F(1,44) 0.07, p 0.79). As reported in Fig. 5 , posthoc analysis con®rmed that sympathectomy reduced NPY concentrations in the eye (vehicle saline: 0.92 AE 0.054 pmol/g; 6-OHDA saline: 0.64 AE 0.11 pmol/g; p , 0.05), in the heart (vehicle saline: 5.80 AE 0.57 pmol/g; 6-OH-DA saline: 3.52 AE 0.17 pmol/g; p , 0.05) and in the spleen (vehicle saline: 29.6 AE 3.5 pmol/g; 6-OHDA saline: 14.6 AE 1.6 pmol/g; p , 0.05). Injection of vehicle-treated mice with CCK-8 increased NPY levels in eye (vehicle CCK-8: 1.510 AE 0.076 pmol/g; vehicle saline: 0.92 AE 0.054 pmol/g; p , 0.05) but not in heart (vehicle CCK-8: 6.19 AE 0.37 pmol/g; vehicle saline: 5.80 AE 0.57 pmol/g; p . 0.05) and spleen (vehicle CCK-8: 29.15 AE 3.08 pmol/g; vehicle saline: 29.60 AE 3.50 pmol/g; p . 0.05). When injected in sympathectomised mice, CCK-8 increased NPY in the heart (5.77 AE 0.32 pmol/g in 6-OHDA CCK-8 vs 3.52 AE 0.17 pmol/g in 6-OHDA saline; p , 0.05) and in the eye (0.860 AE 0.059 pmol/g in 6-OHDA CCK-8 vs 0.640 AE 0.108 pmol/g in 6-OHDA saline; p , 0.05), while it had no effect in spleen (16.51 AE 2.4 pmol/g in 6-OH-DA CCK-8 vs 14.6 AE 1.6 pmol/g in 6-OHDA saline; p . 0.05).
DISCUSSION
Our study demonstrates that administration of CCK-8 is able to up-regulate NGF synthesis and to promote peripheral sympathetic nerve outgrowth in 6-OHDA treated mice. These ®ndings are consistent with our previous observations that administration of CCK-8 promotes recovery of experimentally induced damage of basal forebrain cholinergic neurones [8] and of chemically injured sensory neurones [20] . Our studies also showed that CCK-8 enhances the synthesis of BDNF, a neurotrophin that plays a signi®cant role in the growth and functioning of a variety of brain and peripheral neurones [21] .
A key question raised by these observations is whether CCK-8 exerts any direct action on lesioned nerves. Findings recently published by our group suggested that the action of CCK is mediated through the modulation of endogenous NGF synthesis and/or release. It was found that inhibition of endogenous NGF by intracerebroventricular injection of NGF antibody prevented the CCKinduced expression of cholineacetyltransferase (ChAT) in forebrain cholinergic neurones of brain lesioned mice [8] . The hypothesis that the effect of CCK-8 is mediated by an increase of endogenous NGF is also suggested by the ®nding that CCK-8 affects the expression of NPY, a neuropeptide known to be regulated by NGF [19] . Moreover, the observation that functional recovery of peripheral sensory injured nerve ®bres of adult mice injected with CCK-8 is associated with up-regulation of substance P (SP) and calcitonin gene-related peptide (CGRP) [20] , which are known to be regulated by NGF [11, 22] , supports this hypothesis.
Our results also demonstrate that the effects of CCK-8 on chemically sympathectomised peripheral nerve ®bres can affect not only NGF protein but also the expression of the NGF gene, though this effect is more marked in the eye and in the heart and much less in the spleen. Since 6-OHDA differentially alters the NGFmRNA expression in the eye, heart and spleen, it is possible that the action of CCK-8 depends on the different local responses to peripheral nerve lesions [12] and/or on the ability of different peripheral organs to synthesise and release neurotrophins. The evidence that the spleen is only weakly affected by 6-OHDA, compared to the heart and the eye [12] , seems to support this hypothesis. In summary, the evidence that i.p. injection with CCK-8 stimulates NGF synthesis in the periphery suggests that CCK-8 can be potentially useful in studying the mechanisms involved in peripheral nerve degeneration/regeneration associated with peripheral sympathetic nerve de®cits. It has recently been reported that NGF exerts a protective action against post-ischaemic dysfunction of coronary sympathetic innervation in dogs [23] while autonomic failure in patients affected by longstanding dizziness is associated with reduction of peripheral NGF synthesis [24] . Our ®ndings suggest the hypothesis that CCK-8 can be used to overcome or reduce NGF-related peripheral autonomic dysfunction.
CONCLUSION
Recent studies suggest that NGF could be clinically useful in promoting healing in human peripheral neuropathies such as those induced by diabetes [5] or AIDS [25] . Exogenous administration of NGF has also been shown to cause peripheral hyperalgesia, thus rendering the clinical utilisation of this molecule dif®cult [5, 25] . Our ®ndings demonstrate that CCK-8 is able to enhance NGF protein synthesis in peripheral tissues, suggesting that CCK-8 is potentially useful in promoting regeneration of injured peripheral sympathetic nerve ®bres that are receptive to the action of NGF.
